EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Finch Therapeutics Group's Enterprise Value is $8.70 Mil.
Finch Therapeutics Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-31.52 Mil. Therefore, Finch Therapeutics Group's EV-to-FCF for today is -0.28.
The historical rank and industry rank for Finch Therapeutics Group's EV-to-FCF or its related term are showing as below:
FNCH'
s EV-to-FCF Range Over the Past 10 Years
Min: -25.93 Med: -0.29 Max: 0.43
Current: -0.28
During the past 5 years, the highest EV-to-FCF of Finch Therapeutics Group was 0.43. The lowest was -25.93. And the median was -0.29.
FNCH's EV-to-FCF is ranked worse than 100% of 392
companies
in the Biotechnology industry
Industry Median: 4.57
vs FNCH: -0.28
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Finch Therapeutics Group's EV-to-FCF
For the Biotechnology subindustry, Finch Therapeutics Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Finch Therapeutics Group's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Finch Therapeutics Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Finch Therapeutics Group's EV-to-FCF falls into.
Finch Therapeutics Group's current Enterprise Value is $8.70 Mil.
Finch Therapeutics Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Finch Therapeutics Group (NAS:FNCH) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Finch Therapeutics Group's PE Ratio for today is calculated as:
Finch Therapeutics Group's share price for today is $2.30.
Finch Therapeutics Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-47.630.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Finch Therapeutics Group EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Finch Therapeutics Group's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Finch Therapeutics Group (Finch Therapeutics Group) Business Description
Finch Therapeutics Group Inc is a clinical-stage microbiome therapeutics company. It is leveraging Human-First Discovery platform to develop a novel class of orally administered biological drugs. It is developing novel therapeutics to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The lead product candidate is CP101 which delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FNCH has been successfully added to your 